Document is current
Any future updates will be listed below
-
Authors
Arzamasov, Aleksandr A. https://orcid.org/0000-0002-4150-4817
Rodionov, Dmitry A. https://orcid.org/0000-0002-0939-390X
Hibberd, Matthew C. https://orcid.org/0000-0001-6520-677X
Guruge, Janaki L.
Kent, James E.
Kazanov, Marat D. https://orcid.org/0000-0002-2314-5507
Leyn, Semen A. https://orcid.org/0000-0002-9886-9120
Elane, Marinela L.
Sejane, Kristija
Furst, Annalee
Bode, Lars
Barratt, Michael J. https://orcid.org/0000-0003-3794-1296
Gordon, Jeffrey I. https://orcid.org/0000-0001-8304-3548
Osterman, Andrei L. https://orcid.org/0000-0002-3810-9824
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK30292, DK30292, DK30292, DK30292, DK30292, DK30292, DK30292, DK30292, DK30292, DK30292)
Family Larsson-Rosenquist Foundation
- License Information
-
More Information
Article History
Received: 3 July 2024
Accepted: 5 June 2025
First Online: 16 July 2025
Competing interests
: D.A.R. and A.L.O. are co-founders of Phenobiome Inc., a company pursuing the development of personalized nutritional solutions to balance the gut microbiome. L.B. is a co-inventor on patent applications related to the use of HMOs in preventing necrotizing enterocolitis and other inflammatory diseases. The other authors declare no competing interests.
